BCL2 associated agonist of cell deathGenealiases: BBC2 · BCL2L8
Q-omics provides the consensus-scored BAD profile across patient tissues and cancer cell-line models. BAD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BAD is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BAD RNA expression shows 19,082 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where BAD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAD survival associations across molecular data types. BAD RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAD RNA expression–survival associations across cancer types. High BAD expression shows unfavorable associations in ACC, UVM, LIHC, KICH, LGG and DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BAD RNA expression.
This table summarizes BAD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BAD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAD shows lower tumor expression in COAD, KICH and THCA and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher BAD RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p < 0.001).
This table shows molecular features associated with BAD in patient tissues and cancer cell lines. In patient samples, BAD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BAD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
